[go: up one dir, main page]

CY1118347T1 - Συνθετικα ανοσοενισχυτικα γλυκοπυρανοζυλο-λιπιδιων και συνθεσεις εμβολιων που τα περιεχουν - Google Patents

Συνθετικα ανοσοενισχυτικα γλυκοπυρανοζυλο-λιπιδιων και συνθεσεις εμβολιων που τα περιεχουν

Info

Publication number
CY1118347T1
CY1118347T1 CY20161100990T CY161100990T CY1118347T1 CY 1118347 T1 CY1118347 T1 CY 1118347T1 CY 20161100990 T CY20161100990 T CY 20161100990T CY 161100990 T CY161100990 T CY 161100990T CY 1118347 T1 CY1118347 T1 CY 1118347T1
Authority
CY
Cyprus
Prior art keywords
vaccine compositions
glycopyranozyl
immunosuppressants
compositions containing
lipid synthetic
Prior art date
Application number
CY20161100990T
Other languages
English (en)
Inventor
Steven G Reed
Darrick Carter
Original Assignee
Infectious Disease Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Research Institute filed Critical Infectious Disease Research Institute
Publication of CY1118347T1 publication Critical patent/CY1118347T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Παρέχονται ενώσεις, ιδίως, ενώσεις ανοσοενισχυτικών γλυκοπυρανοζυλο-λιπιδίων (GLA), που έχουν την ακόλουθη δομή (I): (I) ή φαρμακευτικά αποδεκτό άλας αυτής, όπου L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, είναι όπως ορίζονται εδώ. Παρέχονται επίσης φαρμακευτικές συνθέσεις, συνθέσεις εμβολίων, και σχετικές μέθοδοι για επαγωγή ή ενίσχυση ανοσοαποκρίσεων.
CY20161100990T 2009-06-05 2016-10-05 Συνθετικα ανοσοενισχυτικα γλυκοπυρανοζυλο-λιπιδιων και συνθεσεις εμβολιων που τα περιεχουν CY1118347T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18470309P 2009-06-05 2009-06-05
PCT/US2010/037466 WO2010141861A1 (en) 2009-06-05 2010-06-04 Synthetic glucopyranosyl lipid adjuvants

Publications (1)

Publication Number Publication Date
CY1118347T1 true CY1118347T1 (el) 2017-06-28

Family

ID=43298190

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100990T CY1118347T1 (el) 2009-06-05 2016-10-05 Συνθετικα ανοσοενισχυτικα γλυκοπυρανοζυλο-λιπιδιων και συνθεσεις εμβολιων που τα περιεχουν

Country Status (22)

Country Link
US (4) US8722064B2 (el)
EP (2) EP2437753B1 (el)
JP (3) JP5830015B2 (el)
CN (2) CN102481312B (el)
AU (1) AU2010256461B2 (el)
BR (1) BRPI1011072B1 (el)
CA (1) CA2764374C (el)
CY (1) CY1118347T1 (el)
DK (1) DK2437753T3 (el)
ES (1) ES2606563T3 (el)
HR (1) HRP20161585T1 (el)
HU (1) HUE031051T2 (el)
IL (2) IL216669A (el)
LT (1) LT2437753T (el)
MX (3) MX393384B (el)
PL (1) PL2437753T3 (el)
PT (1) PT2437753T (el)
RU (3) RU2732574C2 (el)
SI (1) SI2437753T1 (el)
SM (1) SMT201600437B (el)
TW (2) TWI494125B (el)
WO (1) WO2010141861A1 (el)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
FI2068918T4 (fi) 2006-09-26 2024-08-16 Access To Advanced Health Inst Synteettistä adjuvanttia sisältävä rokotekoostumus
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US20110305748A1 (en) 2010-03-11 2011-12-15 Immune Design, Corp. Vaccines for Pandemic Influenza
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2012112691A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP3984551A1 (en) 2011-12-02 2022-04-20 Rhode Island Hospital Vaccine for falciparum malaria
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
KR20150022996A (ko) 2012-06-08 2015-03-04 아두로 바이오테크 암 면역요법을 위한 조성물 및 방법
KR101850319B1 (ko) 2012-07-13 2018-04-20 웨이브 라이프 사이언시스 리미티드 비대칭 보조 그룹
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
KR20150095668A (ko) 2012-12-13 2015-08-21 아두로 바이오테크, 인코포레이티드 규정된 입체화학을 갖는 환식 퓨린 다이뉴클레오타이드를 포함하는 조성물, 그리고 이의 제조 방법 및 용도
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
ES2982836T3 (es) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
SMT201900635T1 (it) 2013-05-18 2020-01-14 Univ California Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
WO2015035010A1 (en) * 2013-09-05 2015-03-12 Immune Design Corp. Vaccine compositions for drug addiction
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
BR112016006245A2 (pt) 2013-10-03 2017-08-01 Nitto Denko Corp composição de vacina de mucosa
TW201601750A (zh) 2013-10-03 2016-01-16 Nitto Denko Corp 注射疫苗組合物
CA2923026A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Nasal mucosal vaccine composition
AU2014330336A1 (en) 2013-10-03 2016-03-17 Nitto Denko Corporation Mucosal vaccine composition
BR112016015422A2 (pt) 2013-12-31 2017-10-24 Infectious Disease Res Inst formulações de vacina de frasco único
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
AU2015209575A1 (en) * 2014-01-21 2016-07-21 Immune Design Corp. Compositions for use in the treatment of allergic conditions
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
EP3381467A4 (en) 2015-11-27 2019-06-05 Nitto Denko Corporation PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING A PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION
IL319503A (en) 2016-05-16 2025-05-01 Access To Advanced Health Inst PEGylated liposomes and methods of use
CA3023968A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
KR20190009308A (ko) 2016-05-21 2019-01-28 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11633411B2 (en) 2016-10-04 2023-04-25 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
US10874734B2 (en) * 2016-11-25 2020-12-29 Mogam Institute For Biomedical Research Varicella zoster virus vaccine
EP3560512A4 (en) 2016-12-26 2020-07-22 Mogam Institute for Biomedical Research COMPOSITION OF VACCINE AGAINST ZONA
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
IL271384B2 (en) 2017-06-15 2025-02-01 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and their uses
JP7339942B2 (ja) * 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
JP2020533354A (ja) 2017-09-13 2020-11-19 サノフィ・パスツールＳａｎｏｆｉ Ｐａｓｔｅｕｒ ヒトサイトメガロウイルス免疫原性組成物
MX2020008417A (es) 2018-02-12 2020-11-11 Inimmune Corp Ligandos de receptores de tipo toll.
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
WO2020109365A1 (en) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
PL3942028T3 (pl) 2019-03-18 2023-10-23 Janssen Pharmaceuticals, Inc. Sposób wytwarzania biokoniugatów polisacharydów antygenu O E. coli, zawierające je kompozycje oraz sposoby ich zastosowania
SG11202110301TA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
HUE068985T2 (hu) 2020-01-16 2025-02-28 Janssen Pharmaceuticals Inc FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
AU2021406131A1 (en) 2020-12-23 2023-08-03 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
JP2024535353A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション 感染性疾患に対するｒｎａワクチン
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法
JP2024535351A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション 乾燥ナノ粒子組成物
CN117105888A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 一种mpla酰基链中间体的合成方法
KR20250031230A (ko) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4029762A (en) * 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4420558A (en) 1981-02-12 1983-12-13 Janssen Pharmaceutica N.V. Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4420461A (en) 1982-05-26 1983-12-13 Ortho Diagnostic Systems Inc. Agglutination-inhibition test kit for detecting immune complexes
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4743540A (en) 1983-09-27 1988-05-10 Memorial Sloan-Kettering Cancer Center Method for diagnosis of subclassifications of common varied immunodeficiency disease group
US5147785A (en) 1983-11-01 1992-09-15 Amtl Corporation Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells
US4614722A (en) 1983-11-01 1986-09-30 Pasula Mark J Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4629722A (en) 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4659659A (en) 1985-01-22 1987-04-21 Monsanto Company Diagnostic method for diseases having an arthritic component
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4746742A (en) 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
US6544728B1 (en) * 1986-01-22 2003-04-08 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2
US5310651A (en) 1986-01-22 1994-05-10 Institut Pasteur DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2
US6514691B1 (en) 1986-01-22 2003-02-04 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2
US6054565A (en) * 1986-03-03 2000-04-25 Institut Pasteur Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH0755906B2 (ja) 1986-07-01 1995-06-14 第一製薬株式会社 ジサツカライド誘導体含有鎮痛剤
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US5565209A (en) 1987-03-17 1996-10-15 Akzo Nobel N.V. Adjuvant mixture
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
DK0382271T3 (da) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
DE69031556T2 (de) 1989-07-25 1998-05-14 Smithkline Beecham Biologicals S.A., Rixensart Antigene sowie Verfahren zu deren Herstellung
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5124141A (en) 1990-06-14 1992-06-23 Flow Incorporated Method for diagnosing malaria
US5162990A (en) 1990-06-15 1992-11-10 The United States Of America As Represented By The United States Navy System and method for quantifying macrophage phagocytosis by computer image analysis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE356142T1 (de) 1991-07-19 2007-03-15 Univ Queensland Impfstoff gegen humanes papillomavirus (typ 18)
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
DK0596032T4 (da) 1991-07-25 2004-07-26 Idec Pharma Corp Induktion af cytotoksiske T-lymfocytsvar
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
ATE132742T1 (de) 1991-08-16 1996-01-15 Vical Inc Zusammensetzung und verfahren zur behandlung von zystischer fibrose
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
US6057427A (en) * 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US5286718A (en) 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPH05328975A (ja) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
DE122007000094I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5411865A (en) * 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
AU688759C (en) 1993-03-09 2006-12-21 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5532133A (en) 1993-06-02 1996-07-02 New York University Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US6033928A (en) 1993-11-02 2000-03-07 Matsushita Electric Industrial Co., Ltd. Method of manufacturing aggregate of semiconductor micro-needles
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
SE9403137D0 (sv) 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
ES2264563T3 (es) 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
AU4357396A (en) 1995-02-08 1996-08-27 Takara Shuzo Co., Ltd. Cancer control
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
AU7254396A (en) 1995-09-29 1997-04-17 Eisai Research Institute Method for treating alcoholic liver disease
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5846758A (en) 1995-11-30 1998-12-08 His Excellency Ghassan I. Shaker Method for diagnosing autoimmune diseases
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
SE9600648D0 (sv) 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
DK0909562T3 (da) * 1996-07-03 2005-08-22 Eisai Co Ltd Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
ATE229073T1 (de) 1996-09-06 2002-12-15 Univ California Protein e25a, methoden zu dessen herstellung und anwendung
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
JPH10131046A (ja) 1996-10-29 1998-05-19 Nikka Chem Co Ltd 繊維の耐久性ｐＨ緩衝加工方法
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US7033598B2 (en) * 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
DE19654221B4 (de) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Leitungsanschlußschaltkreis
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
AR012035A1 (es) 1997-02-25 2000-09-27 Corixa Corp Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
BR9811262A (pt) 1997-04-01 2000-10-17 Ribi Immunochem Research Inc Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU7983198A (en) 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
CA2297374A1 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US6368604B1 (en) * 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
US7012134B2 (en) 1998-01-26 2006-03-14 Human Genome Sciences, Inc. Dendritic enriched secreted lymphocyte activation molecule
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1584685B1 (en) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
JP2002502884A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン
US6596501B2 (en) 1998-02-23 2003-07-22 Fred Hutchinson Cancer Research Center Method of diagnosing autoimmune disease
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
DE69933200T2 (de) 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
AU3560399A (en) 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
HU225844B1 (en) 1998-05-07 2007-10-29 Corixa Corp Adjuvant composition and its use
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
EP1097208A2 (en) 1998-07-14 2001-05-09 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
AU766994B2 (en) 1998-08-25 2003-10-30 Ronald J. Gallenberg Beach cleaning apparatus and method
EP1111390A4 (en) 1998-09-01 2007-11-14 Eisai R&D Man Co Ltd METHOD FOR EVALUATING INJECTIONS CONTAINING LIPID A ANALOGS
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2000095694A (ja) * 1998-09-24 2000-04-04 Sankyo Co Ltd 新規な医療用薬剤
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
WO2000018929A2 (en) 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
DE122007000087I1 (de) * 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) * 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
WO2000042994A2 (en) 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US20030170249A1 (en) 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
WO2000062066A1 (fr) 1999-04-07 2000-10-19 Hitachi Chemical Co., Ltd. PROCEDE D'EVALUATION DE MALADIES AUTO-IMMUNES, PROCEDE DE DETECTION D'ANTICORPS DE PROTEINE ANTI-Reg ET DIAGNOSTICS POUR MALADIES AUTO-IMMUNES
CZ303515B6 (cs) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
US6685699B1 (en) * 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
EP1206533A1 (en) 1999-08-26 2002-05-22 Pharmacia AB Novel response element
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
JP2003514824A (ja) 1999-11-15 2003-04-22 ビオミラ，インコーポレーテッド 合成脂質−ａ類似体およびその使用
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6587792B1 (en) 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
EP1122542A1 (en) 2000-02-01 2001-08-08 Anda Biologicals S.A. Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE60134134D1 (de) 2000-05-19 2008-07-03 Corixa Corp Prophylaktische und therapeutische behandlung von ten mit verbindungen, die auf monosacchariden basieren
US6875610B2 (en) 2000-05-31 2005-04-05 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
JP2004510746A (ja) 2000-10-06 2004-04-08 パラディース，ハー．，ヘンリッヒ 免疫調節効果を有する自家ワクチンとしてのカイバードラッグ
EP1326638B9 (en) 2000-10-18 2008-02-20 GlaxoSmithKline Biologicals S.A. Vaccines against cancers
WO2003004525A2 (en) * 2001-01-26 2003-01-16 Walter Reed Army Institute Of Research Isolation and purification of plasmodium falciparum merozoite protein-142
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
AU2002306896B2 (en) 2001-03-26 2007-04-26 Walter Reed Army Institute Of Research Plasmodium falciparum AMA-1 protein and uses thereof
US7029685B2 (en) 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) * 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
US7078180B2 (en) 2001-09-05 2006-07-18 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
US6908453B2 (en) * 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2003066065A1 (en) 2002-02-04 2003-08-14 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
RU2288723C2 (ru) * 2002-02-04 2006-12-10 Корикса Корпорейшн Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
ATE457733T1 (de) 2002-05-09 2010-03-15 Oncothyreon Inc Lipid-a- und andere kohlenhydrat-liganden-analoga
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
FR2862062B1 (fr) 2003-11-06 2005-12-23 Oreal Lipide a et composition topique, notamment cosmetique, le comprenant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
FI2068918T4 (fi) * 2006-09-26 2024-08-16 Access To Advanced Health Inst Synteettistä adjuvanttia sisältävä rokotekoostumus
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP5328975B2 (ja) 2012-12-19 2013-10-30 ルネサスエレクトロニクス株式会社 Ｒｆパワーモジュール
WO2014172637A1 (en) * 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis

Also Published As

Publication number Publication date
IL216669A (en) 2016-04-21
US20140322268A1 (en) 2014-10-30
EP2437753A1 (en) 2012-04-11
US9480740B2 (en) 2016-11-01
ES2606563T3 (es) 2017-03-24
MX2011012836A (es) 2012-04-20
CN102481312B (zh) 2015-07-15
JP5830015B2 (ja) 2015-12-09
IL216669A0 (en) 2012-02-29
TW201102085A (en) 2011-01-16
EP2437753A4 (en) 2012-12-05
JP2017137327A (ja) 2017-08-10
US20100310602A1 (en) 2010-12-09
SMT201600437B (it) 2017-01-10
WO2010141861A1 (en) 2010-12-09
RU2015129468A3 (el) 2019-01-21
US10632191B2 (en) 2020-04-28
JP2016028042A (ja) 2016-02-25
TWI549688B (zh) 2016-09-21
CN102481312A (zh) 2012-05-30
MX360448B (es) 2018-11-01
US8722064B2 (en) 2014-05-13
BRPI1011072A2 (pt) 2016-04-12
IL242992B (en) 2018-01-31
CN105131051A (zh) 2015-12-09
PT2437753T (pt) 2016-11-23
TW201544120A (zh) 2015-12-01
RU2020129844A (ru) 2022-03-10
EP2437753B1 (en) 2016-08-31
CA2764374A1 (en) 2010-12-09
MX393384B (es) 2025-03-24
SI2437753T1 (sl) 2016-12-30
AU2010256461B2 (en) 2016-03-17
RU2560182C2 (ru) 2015-08-20
EP3124491B1 (en) 2019-10-30
RU2015129468A (ru) 2015-12-27
TWI494125B (zh) 2015-08-01
PL2437753T3 (pl) 2017-03-31
DK2437753T3 (en) 2016-12-19
EP3124491A1 (en) 2017-02-01
BRPI1011072B1 (pt) 2021-09-28
US20180028649A1 (en) 2018-02-01
HUE031051T2 (en) 2017-06-28
JP6251431B2 (ja) 2017-12-20
CN105131051B (zh) 2020-07-10
US9814772B2 (en) 2017-11-14
CA2764374C (en) 2019-11-19
JP2012528892A (ja) 2012-11-15
LT2437753T (lt) 2016-12-12
HRP20161585T1 (hr) 2016-12-30
US20170182155A1 (en) 2017-06-29
AU2010256461A1 (en) 2012-01-12
RU2732574C2 (ru) 2020-09-21

Similar Documents

Publication Publication Date Title
CY1118347T1 (el) Συνθετικα ανοσοενισχυτικα γλυκοπυρανοζυλο-λιπιδιων και συνθεσεις εμβολιων που τα περιεχουν
CY1119545T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1119544T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
ECSP18032223A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO DE USO
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CY1116143T1 (el) Παραγωγα χρωμενονης με αντικαρκινικη δραση
CY1117792T1 (el) Ανταγωνιστες toy trpv4
BR112015014462A2 (pt) vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos
PH12015501445A1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
DOP2014000081A (es) Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas
SMT201400076B (it) Formulazioni farmaceutiche contro l'uso improprio di medicinali
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
EA201590862A1 (ru) Фармацевтические композиции
PL2760878T3 (pl) Pochodne estra-1,3,5(10),16-tetraeno-3-karboksyamidowe, sposób ich wytwarzania, preparaty farmaceutyczne, które je zawierają, i ich zastosowanie do wytwarzania leków
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
EP2133092A4 (en) Oral vaccine
CY1114757T1 (el) Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
EA201171366A1 (ru) Противоопухолевая комбинация, содержащая ave8062 и сорафениб
EA201492029A1 (ru) N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид